Afexa Life Sciences Inc.

Afexa Life Sciences Inc.

March 28, 2008 08:00 ET

CV Technologies Announces Appointment of New CFO

EDMONTON, ALBERTA--(Marketwire - March 28, 2008) - CV Technologies Inc. (TSX:CVQ) today announced the appointment of Nazir Noormohamed as Chief Financial Officer, effective immediately. He replaces former Chief Financial Officer Gordon Brown, who has left the Company.

"Nazir will be an important part of our team as we search for a permanent CFO with the necessary skills to help our Company achieve dynamic and profitable long-term growth," said Dr. Jacqueline Shan, President, Chief Executive Officer and Chief Scientific Officer.

Mr. Noormohamed is a Certified Management Accountant with nearly 25 years of experience in executive roles for public and private companies, including 11 years as a CFO. Mr. Noormohamed will be working with CV Technologies on contract until a permanent replacement CFO is found.


CV Technologies is a global leader in the development and commercialization of naturally derived, evidence-based, natural therapeutics for disease prevention and health maintenance. Its lead product - COLD-fX® - approved by Health Canada, prevents and relieves cold and flu infections by strengthening the immune system. It is Canada's #1 selling cold and flu remedy (ACNielsen's MarketTrack Drug Service for Cold Remedies, Natural Supplements & Vitamins Categories for the 52 weeks ending December 22, 2007).

Contact Information